Acetylcysteine protective against TB drug-induced hepatotoxicity
- PDF / 122,864 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 39 Downloads / 183 Views
1
Acetylcysteine protective against TB drug-induced hepatotoxicity Acetylcysteine appears to have protective effects against anti-tubercular drug-induced hepatotoxicity, according to a randomised trial. Sixty new tuberculosis patients (aged ≥ 60 years) were randomised to receive daily doses of isoniazid, rifampicin, pyrazinamide and ethambutol, with (n = 32) or without acetylcysteine. Liver enzymes and bilirubins were assessed at baseline, and at 1 and 2 weeks of treatment, or whenever patients presented with clinical symptoms of hepatotoxicity. After 1 and 2 weeks of treatment, mean values of AST and ALT were significantly higher in the group that did not receive acetylcysteine versus the group that did receive acetylcysteine. Hepatotoxicity occurred among 12 patients (37.5%) in the group without acetylcysteine, and in none of the acetylcysteine recipients. The mean treatment duration before hepatotoxicity onset was 4.67 days, and serum transferases were normalised within 8.17 days after treatment cessation, say the researchers. Baniasadi S, et al. Protective effect of N-acetylcysteine on antituberculosis druginducedhepatotoxicity. European Journal of Gastroenterology and Hepatology : 10 May 2010. Available from: URL: http://dx.doi.org/10.1097/ 803019498 meg.0b013e32833aa11b
0114-9954/10/1307-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 26 Jun 2010 No. 1307
Data Loading...
